AU2004296531A1 - The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist - Google Patents
The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist Download PDFInfo
- Publication number
- AU2004296531A1 AU2004296531A1 AU2004296531A AU2004296531A AU2004296531A1 AU 2004296531 A1 AU2004296531 A1 AU 2004296531A1 AU 2004296531 A AU2004296531 A AU 2004296531A AU 2004296531 A AU2004296531 A AU 2004296531A AU 2004296531 A1 AU2004296531 A1 AU 2004296531A1
- Authority
- AU
- Australia
- Prior art keywords
- disorder
- ucl
- disorders
- serotonin reuptake
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52949103P | 2003-12-15 | 2003-12-15 | |
| US60/529,491 | 2003-12-15 | ||
| DKDKPA200301854 | 2003-12-15 | ||
| DKPA200301854 | 2003-12-15 | ||
| PCT/DK2004/000862 WO2005056056A2 (en) | 2003-12-15 | 2004-12-14 | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004296531A1 true AU2004296531A1 (en) | 2005-06-23 |
Family
ID=34680191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004296531A Abandoned AU2004296531A1 (en) | 2003-12-15 | 2004-12-14 | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1696896A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007513896A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004296531A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0415899A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20063267L (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005056056A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG146683A1 (en) | 2003-09-17 | 2008-10-30 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as serotonin receptor modulators |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| CN101809021B (zh) | 2007-09-11 | 2013-04-24 | 雅培制药有限公司 | 八氢-吡咯并[3,4-b]吡咯n-氧化物 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP7579028B2 (ja) * | 2020-12-23 | 2024-11-07 | 上海雲晟研新生物科技有限公司 | ビラゾドン医薬組成物、その製造方法及び応用 |
| AU2024230525A1 (en) * | 2023-02-28 | 2025-10-09 | Biohaven Therapeutics Ltd. | Methods for treating obsessive compulsive related disorders, tic disorders and glutamate excitotoxicity related disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020279A1 (en) * | 1997-10-17 | 1999-04-29 | Eli Lilly And Company | Potentiation of pharmaceuticals |
| HK1040055B (zh) * | 1998-05-22 | 2005-04-01 | 伊莱利利公司 | 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 |
| BR9911068A (pt) * | 1998-05-29 | 2001-02-06 | Lilly Co Eli | Terapia combinada para tratamento de distúrbios bipolares |
| EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
-
2004
- 2004-12-14 WO PCT/DK2004/000862 patent/WO2005056056A2/en not_active Ceased
- 2004-12-14 AU AU2004296531A patent/AU2004296531A1/en not_active Abandoned
- 2004-12-14 EP EP04803015A patent/EP1696896A2/en not_active Withdrawn
- 2004-12-14 JP JP2006543369A patent/JP2007513896A/ja not_active Withdrawn
- 2004-12-14 BR BRPI0415899-7A patent/BRPI0415899A/pt not_active IP Right Cessation
-
2006
- 2006-07-13 NO NO20063267A patent/NO20063267L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1696896A2 (en) | 2006-09-06 |
| JP2007513896A (ja) | 2007-05-31 |
| WO2005056056A2 (en) | 2005-06-23 |
| WO2005056056A3 (en) | 2006-02-02 |
| NO20063267L (no) | 2006-07-13 |
| BRPI0415899A (pt) | 2007-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100267772A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Agomelatine | |
| CA2490638C (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| JP2009531435A (ja) | うつ病の治療用の新規な治療組み合わせ | |
| EP1696896A2 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| US20070066601A1 (en) | Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| US20060223857A1 (en) | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | |
| JP2007513896A6 (ja) | セロトニン再取り込み阻害剤およびヒスタミン3受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用 | |
| CA2537747A1 (en) | The combination of a serotonin reuptake inhibitor and loxapine | |
| US20070042014A1 (en) | Combination of a serotonin reuptake inhibitor and loxapine | |
| US20080167290A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Amoxapine | |
| MXPA06005127A (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| ZA200409278B (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| CA2579520A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| CA2537757A1 (en) | The combination of a serotonin reuptake inhibitor and amoxapine | |
| ZA200601084B (en) | The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS:DELETE PRIORITY DETAILS 60/529,491 15 DEC 2003 US |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |